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ECG monitoring after catheter ablation is a necessary part of care of patients with atrial
fibrillation. A significant number of patients after catheter ablation of atrial fibrillation
have sooner or later arrhythmia recurrence. The riskier the patient the bigger the impact of
a potential arrhythmia and the more intensive effort to monitor ECG after ablation should
be made. An integral part of follow-up of patients after catheter ablation is not only
monitoring for potential arrhythmia recurrence but also monitoring for complications of
ablation, antiarrhythmic and antithrombotic drugs prescription, influencing of atrial
fibrillation development risk factors and considering reablation.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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ablation
ECG monitoring after catheter ablation is a crucial compo-
nent of management of patients with atrial fibrillation
(AF). Symptoms described by the patients themselves can
be quite misleading. Palpitations, clinically suggestive
of AF recurrence, may be caused by mere supraventricularch Society of Cardiology.or ventricular extrasystoles—the diagnosis of AF recurrence
thus cannot be based solely on the subjective description
of heart pounding [1]. On the other hand, extensive
monitoring of patients after ablation has shown that AF
recurrences can be truly asymptomatic [2]. When assessed
just with respect to subjective complaints, ablation in
these asymptomatic patients can be falsely judged as
successful.Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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documented recurrence of arrhythmia between 3 (the initial
transitional period) and 12 months after the procedure with-
out taking any antiarrhythmic medication. Long-term success
is defined as absence of arrhythmia 36 months after the
ablation without any antiarrhythmic medication. Partial suc-
cess can be defined by at least 75% reduction in the frequency
and/or duration of paroxysms of arrhythmia in comparison to
the pre-ablation interval. Any arrhythmia to be considered AF
recurrence after ablation must have a documented duration
of at least 30 s and must occur later than 3 months after
the procedure. AF recurrence within the initial 3 months is
considered an early recurrence and may not be associated
with other AF recurrences in more distant future (see below).
ECG monitoring after ablation can be performed using both
continuous and discontinuous recordings. The more exten-
sive monitoring (more frequently acquired and/or longer ECG
recordings), the higher is the probability of documenting
arrhythmia recurrence [3]. Discontinuous recordings include
planned ECGs during scheduled follow-up visits, ECGs
acquired ad hoc because of clinical complaints, 24 h to 7D
Holter ECG monitoring and external loop recorders. The use
of regular 7D Holter ECG recordings plus ECGs acquired
because of patient complaints makes it possible to detect
about 70% of AF recurrences after ablation [4].
Continuous monitoring refers to monitoring for one or
more years, which was made possible by implantable devices.
The presence of AF can classically be detected by a cardiac
stimulator or by defibrillator with an atrial electrode [5]. An
implantable loop-monitor, offering the possibility to detect
paroxysmal AF during several years, is also available [6].
The standard follow-up in our institution includes an ambu-
latory ECG monitoring aimed at detecting AF recurrences using
7D Holter-ECG after 3, 6, 9, and 12 months following the
ablation. In general, the motivation to detect possible AF
recurrence is higher in patients with higher risk of medical
complications associated with paroxysmal arrhythmia. In other
words—the higher risk in a given patient/the more dangerous
the expected consequences of possible arrhythmia, the more
intensive is the effort to monitor and to detect ECG abnormal-
ities following the ablation.2. Recurrences of arrhythmia after ablation
Recurrences of AF often occur shortly after ablation. Absence
of recurrence in the early post-ablation period is associated
with higher rate of success—85% of patients free from AF
recurrence until 2 weeks after ablation of paroxysmal AF
remain recurrence-free for another 12 months [7]. When
assessing the first 6 weeks after ablation, the absence of
recurrence is associated with markedly higher rate of sinus
rhythm (SR) maintenance for the rest of the first post-
ablation year (84% vs. 38%) [8]. Early recurrences (o3 months
post-ablation) have been linked to higher risk of late recur-
rences [9] and it does not matter when the recurrence is
noted within the first 3 months [7]. Despite this generally
higher risk, however, up to 60% patients with early AF
recurrence are free from another AF recurrence after 3
months following the ablation. The first three months post-ablation are thus viewed as a transitional period during
which AF recurrences are not always considered treatment
failure.
Most AF recurrences after ablation are caused by reconnec-
tion of pulmonary veins (PVs). However, some early AF
recurrences may be caused by an inflammatory reaction at
the site of radiofrequency energy aplication [10] or by delayed
effect of radiofrequency (RF) ablation [11]. In some cases,
arrhythmias may even be triggered by temporary dysbalance
of autonomous nervous system following the ablation [12]. As
many as 15% of patients complain of higher than pre-ablation
AF paroxysm rate [13]. These transitional influences may
eventually form the basis of long-term absence of arrhythmia
even in patients with documented early AF recurrence after
catheterization.
Inflammatory process may thus be one of the possible
causes of early post-ablation AF recurrence. The possibility
of its alleviation and of AF recurrence reduction was assessed
in a randomized study [14]. At the day of ablation, corticoster-
oids were given intravenously, followed by oral administration
of prednisolone for 3 days. Early recurrence within 3 days of
ablation was assessed and was found to be lower in the group
treated with corticosteroids. Patients treated with corticoster-
oids also had lower number of recurrences 14 months post-
ablation (85% vs. 71%). Despite data from this trial, peri-
ablation corticosteroid use has not become a part of common
clinical practice.
When AF recurrence does occur in the early transitional
period, it is prudent to aim at restoring the SR. Persistent AF
leads—as early as after 24 h—to anatomical and electric
remodeling changes in the atrial myocardium, facilitating
the persistence of re-entry circuits and increasing the activity
of AF triggers. These changes further add to the persistence
of arrhythmia and form a vicious circle, markedly supporting
the long-term AF persistence [15,16]. Cardioversion for per-
sistent arrhythmias within 30 days of ablation is associated
with higher rate of long-term SR maintenance [17].
Antiarrhythmics are given to all patients for the above
reasons for at least 3 months post-ablation in many centers
[13]. This short-term antiarrhythmic therapy is associated
with decrease in the number of early AF recurrences follow-
ing ablation. On the other hand, it has no influence on
delayed AF recurrences [8]. It is thus not quite clear whether
it is necessary to keep patients after the AF ablation on
temporary antiarrhythmic treatment. While the early transi-
tional post-ablation period of stabilization is bridged with
less arrhythmia recurrences, long-term recurrences remain
uninfluenced by the initial temporary antiarrhythmic ther-
apy. When antiarrhythmics are given persistently, long-term
recurrences decrease, of course, but the possibility to refrain
from antiarrhythmic treatment is one of the goals of ablation.
In our center, we discontinue antiarrhythmics in all patients
following ablation of paroxysmal AF; individual approach is
adopted after ablation of persistent AF.
About 20% of patients who were free from AF recurrence for
1 year post-ablation experience the arrhythmia recurrence
within the next 1–4 years [18,19]. The highest probability of
delayed AF recurrence is noted in patients with a history of
persistent AF before the ablation [20]. Antiarrhythmic therapy
is initiated in our center following post-ablation AF
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well tolerated before ablation; should another recurrence
occur or should antiarrhythmics be poorly tolerated, re-
ablation is indicated. If arrhythmia recurrence is diagnosed
in patients with paroxysmal AF who do not wish to be on
long-term antiarrhythmic medication, re-ablation is indi-
cated even without trying antiarrhythmics. Individual
approach is certainly always warranted. In our center, 81%
of patients in the past year were free from AF recurrence 12
months after the ablation of paroxysmal AF, 89% of which
were without any antiarrhythmic therapy 1 year post-
ablation.
AF recurrences following ablation can be expected in
20–40% of patients [21]. Since up to 60% of patients with
early AF recurrence within 3 months post-ablation have no
other AF recurrences, re-ablation should not be indicated
before 3 months after the procedure. Exception can be
made in patients with highly symptomatic atrial tachycardia
that does not respond to antiarrhythmics and recurs after
cardioversion. Re-ablation can clearly be performed earlier in
these cases.3. Anticoagulation following catheter ablation
With respect to extensive application of radiofrequency
energy leading to coagulation necrosis and subsequent scar
formation following ablation, it is necessary to use antic-
oagulation therapy in the early post-ablation period. It is
not clear, however, whether it is necessary to continue the
anticoagulation therapy for more than 2–3 months. According
to the provisional recommendation [22], long-term antic-
oagulation following AF ablation is indicated in patients with
high risk of thromboembolic (TE) complications according to
CHADS2 or CHA2DS2VaSc score not taking into account SR
maintenance or absence during follow-up. Anticoagulation
should be continued even in patients without documented AF
recurrence post-ablation because (1) delayed AF recurrences
can occur and (2) many AF paroxysms following the ablation
are asymptomatic. Patients with higher TE risk would thus
not have adequate protection from TE complications, espe-
cially from stroke, in case of undiagnosed arrhythmia recur-
rence. On the other hand, long-term anticoagulation is
associated with the risk of bleeding, its use decreases the
quality of life [23] and according to some smaller studies,
patients after AF ablation have low risk of TE complications after
anticoagulation is discontinued [24,25]. Since we have no data
from any larger randomized clinical trial assessing the safety of
early discontinuation of anticoagulation treatment post-ablation
yet, we should respect the above recommendation to continue
the anticoagulation according to the TE risk, not according to
the documented SR maintenance. While anticoagulation should
thus be recommended to all patients with higher TE risk, one
can still adopt the individualized approach and discontinue the
anticoagulation after 3 months in a patient with persistent SR
following ablation who does not wish to be anticoagulated.
Intensive monitoring of possible asymptomatic AF recurrences
is necessary in these cases with anticoagulation treatment
strategy reassessment in case that recurrence is detected. This
approach is supported by data from a multicenter observationtrial comprising 3444 patients who underwent AF ablation.
Anticoagulation was discontinued in all patients without docu-
mented AF recurrence and without mechanical left atrial
dysfunction. Patients were kept on ASA after anticoagulation
had been discontinued; it was reinstalled in case of AF recur-
rence with respect to the TE risk according to the CHADS2 score.
None of the treated patients experienced a significant TE
complication [26].4. Other pharmacotherapy after catheter
ablation
During ablation performed on the posterior wall of the left
atrium, the ablation catheter can get to the vicinity of
esophagus; esophageal ulcerations can be found endoscopi-
cally in some patients post-ablation. Given the fact that
atrioesophageal fistula formation is a rare, yet a highly
dangerous complication (incidence 0.1–0.25%, mortality over
80%), proton pump inhibitors are administered empirically
in many centers for 1–4 weeks following the ablation.
We administer omeprazole to all patients who underwent
AF ablation for 4 weeks despite the fact that esophagus is
directly visualized using intracardial echocardiography dur-
ing every ablation procedure.
It is also necessary to aim at influencing the risk factors for
AF, especially arterial hypertension, obesity and sleep apnea
syndrome. Treatment for these diagnoses should form an
integral part of care for patients with AF. So far, no convincing
data are available that would confirm any significant impact
of ‘‘up-stream’’ therapy following AF ablation. Administra-
tion of ACE inhibitors in the context of prospective patient
registry was not associated with more successful long-
term SR maintenance after ablation of paroxysmal or persis-
tent AF [27].5. Complex follow-up of patients after
catheter ablation
Each patient who underwent AF ablation should be followed-
up extensively in the medical center where the procedure
was performed and where there is sufficient experience with
possible complications. Control ECG should be obtained
before the patient is discharged and in case that arrhythmia
reccurence is detected, attempts should be made to cure the
arrhythmia before the patient is to be followed on the
outpatient basis. We follow all our patients who underwent
AF ablation telemetrically until the end of hospitalization.
To exclude possible severe early complications of the
ablation, it is always necessary to perform a control trans-
thoracal echocardiography, looking especially for possible
pericardial effusion. When hematoma and/or resistance is
present in the location where the groin was cannulated, it is
prudent to exclude pseudoaneurysm of the femoral artery or
arteriovenous fistula sonographically.
Atrioesophageal fistula usually manifests clinically 2–4
weeks post-ablation as a fever accompanied by neurological
symptoms caused by septic emboli or, in more severe cases,
as a septic shock. If this condition is suspected, CT or MR
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[28,29]. Swallowing of barium paste has a low sensitivity.
Endoscopy should not be performed (when performed, the
highest caution is necessary) since filling the esophagus with
air can lead to massive air embolization to the CNS.
Development of significant pulmonary vein stenosis has
become much less frequent with ablations being performed
further from the pulmonary veins ostia (using wide antral
circumferential ablation). Routine screening for pulmonary
vein stenosis post-ablation is thus being performed in very
few centers nowadays. This complication has to be excluded,
however, when suspicious clinical symptoms appear such as
chest pain, dyspnea, cough, hemoptysis, recurrent pulmon-
ary infections or signs of pulmonary hypertension [30,31].
Cardiac CT or MR or possibly ventilation/perfusion scan is
warranted in these cases.
Beside the search for possible complications, we have to
provide adequate monitoring in order to exclude recurrences
of the arrhythmia, prescription of antiarrhythmics, antith-
rombotic treatment and treatment of the risk factors for AF;
re-ablation should also be indicated if necessary.6. Conclusion
Significant proportion of patients after catheter ablation of
atrial fibrillation experience arrhythmia recurrence during
short-term or long-term follow-up. The intensity of ECG
monitoring following the ablation should be proportional to
the risk in the individual patient or to the expected impact of
possible arrhythmia. While following the patients after abla-
tion, we not only have to monitor for possible arrhythmia
recurrences and ablation complications—we also have to
prescribe the antiarrhythmics, provide antithrombotic treat-
ment, treat the risk factors for AF and indicate possible re-
ablation if necessary.
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